Arcturus Therapeutics (ARCT) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Arcturus Therapeutics (NASDAQ:ARCT) from a hold rating to a buy rating in a research report report published on Saturday, March 30th, ValuEngine reports.

A number of other equities research analysts have also recently commented on ARCT. Zacks Investment Research raised shares of Arcturus Therapeutics from a sell rating to a hold rating in a report on Thursday, March 7th. Roth Capital reaffirmed a buy rating on shares of Arcturus Therapeutics in a report on Wednesday, February 20th. Laidlaw assumed coverage on shares of Arcturus Therapeutics in a research note on Tuesday, February 19th. They issued a buy rating for the company. Finally, Chardan Capital reiterated a buy rating and issued a $18.00 price objective on shares of Arcturus Therapeutics in a research note on Tuesday, March 19th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $13.83.

Shares of NASDAQ:ARCT traded up $0.23 during mid-day trading on Friday, reaching $7.48. The company had a trading volume of 26,394 shares, compared to its average volume of 77,827. The company has a current ratio of 3.33, a quick ratio of 3.33 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $76.83 million, a PE ratio of -3.46 and a beta of 2.17. Arcturus Therapeutics has a one year low of $4.11 and a one year high of $10.00.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Monday, March 18th. The biotechnology company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.41. The company had revenue of $7.58 million during the quarter, compared to the consensus estimate of $3.59 million. Research analysts predict that Arcturus Therapeutics will post -2.11 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its stake in Arcturus Therapeutics by 91.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,744 shares of the biotechnology company’s stock valued at $148,000 after buying an additional 8,008 shares in the last quarter. Worth Venture Partners LLC purchased a new position in shares of Arcturus Therapeutics during the 3rd quarter valued at $290,000. Finally, Creative Planning purchased a new position in shares of Arcturus Therapeutics during the 1st quarter valued at $416,000. Institutional investors and hedge funds own 10.86% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.

Featured Article: Gap Up Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.